Enhancement of drug solubility in supramolecular and colloidal systems

Journal of Pharmaceutical Sciences

Volumn 98, Issue 2, 2009, Pages 484-494

  Süle, András ^a   Szente, Lajos ^b   Csempesz, Ferenc ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

Author keywords

Cyclodextrins; Dissolution; Inclusion compounds; Macromolecular drug delivery; Nanocapsules; Supramolecular associates

Indexed keywords

1 ETHYL 2 PYRROLIDINONE; 2 PYRROLIDONE DERIVATIVE; BETA CYCLODEXTRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; POVIDONE; SIMVASTATIN; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; DRUG CARRIER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYL BETA CYCLODEXTRIN; METHYL-BETA-CYCLODEXTRIN;

AQUEOUS SOLUTION; ARTICLE; COLLOID; COMPLEX FORMATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; MACROMOLECULE; NANOENCAPSULATION; PH; SURFACE TENSION; TEMPERATURE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG STABILITY; SOLUBILITY;

BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; COMPUTER SIMULATION; CYCLODEXTRINS; DRUG CARRIERS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRROLIDINONES; SIMVASTATIN; SOLUBILITY; SURFACE TENSION; TEMPERATURE;

EID: 59849107917     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21437     Document Type: Article

References (33)

1. Istvan ES, Deisenhofer J. 2001. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164.
2. Roberts WC. 1997. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80:106-107.
3. Maron DJ, Fazio S, Linton MF. 2000. Current perspectives on statins. Circulation 101:207-213.
4. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH. 2004. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 274:65-73.
5. Grundy SM. 1988. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33.
6. Tobert JA. 1988. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62:28J-34J.
7. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL. 1994. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Cardiol 74:667-673.
8. Haria M, McTavish D. 1997. Pravastatin: A re-appraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 53:299-336.
9. Hamelin BA, Turgeon J. 1998. Hydrophilicty/lipophilicity: Relevance for the pharma-cology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-36.
10. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. 1993. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA Reductase inhibitor, CI-981. Pharm Res 10:1461-1465.
11. Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
12. Loftsson T, Brewster M. 1996. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
13. Liu L, Guo QX. 2002. The driving forces in the inclusion complexation of cyclodextrins. J Incl Phenom Macro 42:1-14.
14. Szejtli J. 1982. Cyclodextrins and their inclusion complexes. Budapest, Hungary: Akadémiai Kiadó.
15. Prentis RA, Lis Y, Walker SR. 1988. Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25:387-396.
16. Loftsson T, FriCrossed d signriksdóttir H, SigurCrossed d signardóttir AM, Ueda H. 1994. The effect of watersoluble polymers on drug-cyclodextrin complexation. Int J Pharm 110:69-177.
17. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instrum 4:117.
18. European Directorate for the Quality of Medicines & HealthCare: European Pharmacopeia 5th Edition 5.8 Supplement.
19. Validation of analytical procedures: methodology (CPMP/ICH/281/95).
20. Országos Gyógyszerészeti Intézet- Gyógyszerkö-nyvi Osztály - VIII. Magyar Gyó gyszerkönyv (Pharmacopoeia Hungarica VIII.) I./237-239, II./839.
21. Loftsson T, Masson M. 2004. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Deliv Sci Tec 14:35-343.
22. Buvári-Barcza Á, Barcza L. 2000. Changes in the solubility of β-cyclodextrin on complex formation: Guest enforced solubility of β-cyclodextrin inclusion complexes. J Incl Phenom Macro 36:355-380.
23. Puskás I, Barcza L, Szente L, Csempesz F. 2006. Features of the interaction between cyclodextrins and colloidal liposomes. J Incl Phenom Macro 54:89-93.
24. Redenti E, Szente L, Szejtli J. 2000. Drug/cyclodextrin/ hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J Pharm Sci 89:1-8.
25. Süle A, Csempesz F. 2005. Hatóanyag-oldékonyság szabályozása ciklodextrinekkel és kolloidokkal. Abst. Semmelweis Egyetem PhD Tudományos Napok, Budapest, Hungary, p 64.
26. Zia V, Rajewski RA, Stella VJ. 2000. Thermodynamics of binding of neutral molecules to sulfobutyl ether b-Cyclodextrins (SBE-b-CDs): The effect of total degree of substitution. Pharm Res 17:936-941.
27. Junquera E, Aicart E. 1997. Potentiometric study of the encapsulation of ketoprophen by hydroxypropyl-beta-cyclodextrin. Temperature, solvent and salt effects. J Phys Chem B 101:7163-7171.
28. Marcin C, White R, Hirsch C, Ferris F, Sykes R, Houck D, Greasham R, Chartrain M. 1991. Bioconversion of the sodium salt of Simvastatin (MK-733) to 6-desmethyl-6-α-hydroxymethyl Simvastatin. J Ind Microbiol Biotechnol 8:157-164.
29. Iga K, Hussain A, Kashihara T. 1981. New direct calculation of K1: 1 and K1: 2 complexation constants using solubility method. J Pharm Sci 70:108-109.
30. Loftsson T, Stefánsson E, FriCrossed d signriksdóttir H, Kristinsson JK. 1996. Novel CD-based Drug Delivery System. Proceedings of the Eighth International Symposium on Cyclodextrons. p 407-412.
31. Attwood F, Florence AT. 1983. Surfactant systems. Their chemistry, pharmacy and biology. London, UK: Chapman and Hall. pp 361-365.
32. Myers D. 1988. Surfactant science and technology. New York, USA: VCH Publishers. pp 142-145.
33. Loftsson T, Másson M, Brewster ME. 2004. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 93:1091-1099.